Loading this company
BioNTech SE
BNTXPrices in USD
TickerWorth ScoreF36/100
What we think
Priced above our one model’s value of $64.92.
Price
$89.21USD up +$1.50 (+1.71%)
Quoted · Prices are delayed.
Why did it move today?
We could not check today’s news just now.
Is it cheap?
One model only, on today’s numbers
$64.92
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Delayed price used by the model $88.45Prices are delayed.
Changing the inputs, and every lens with its working, is part of Pro. See plans
Is it a good business?
- Valuation100 out of 100
- Growth0 out of 100
- Financial health83 out of 100
- Past performance0 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$116.80 across 20 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It operates in the Biotechnology industry (Healthcare sector), headquartered in Germany. The company employs roughly 7,807 people.
Key stats
We could not load the key statistics just now.
What’s the latest?
No filings or corporate activity on file in the recent window.
Top news
- BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer (opens in a new tab)Benzinga
- Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX) (opens in a new tab)Yahoo
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put (opens in a new tab)Yahoo
- Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Sahin UgurOpen-market sale · $3,453,371.82
- Sahin UgurOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.